The Trypanosomiasis drugs in development market research report provides comprehensive information on the therapeutics under development for Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Trypanosomiasis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Trypanosomiasis and features dormant and discontinued products.
GlobalData tracks 102 drugs in development for Trypanosomiasis by 70 companies/universities/institutes. The top development phase for Trypanosomiasis is preclinical with 59 drugs in that stage. The Trypanosomiasis pipeline has 42 drugs in development by companies and 60 by universities/ institutes. Some of the companies in the Trypanosomiasis pipeline products market are: Drugs for Neglected Diseases initiative, Novartis and University of Dundee.
The key targets in the Trypanosomiasis pipeline products market include Cruzipain, Lanosterol 14 Alpha Demethylase, and Glycylpeptide N Tetradecanoyltransferase.
The key mechanisms of action in the Trypanosomiasis pipeline product include Cruzipain Inhibitor with five drugs in Preclinical. The Trypanosomiasis pipeline products include seven routes of administration with the top ROA being Oral and 13 key molecule types in the Trypanosomiasis pipeline products market including Small Molecule, and Subunit Vaccine.
Trypanosomiasis overview
Trypanosomiasis, also known as sleeping sickness in humans and nagana in animals, is a parasitic disease caused by protozoan parasites of the genus Trypanosoma. There are two main forms of the disease, each caused by different species of Trypanosoma. African trypanosomiasis (sleeping sickness) is transmitted by tsetse flies and is predominantly found in sub-Saharan Africa. It is caused by two subspecies of the parasite: Trypanosoma brucei gambiense causes the chronic form of sleeping sickness, responsible for over 90% of reported cases, which progresses slowly and can last for years without symptoms; Trypanosoma brucei rhodesiense causes the acute form, where symptoms appear within weeks to months and can lead to severe complications if untreated. American Trypanosomiasis (Chagas disease), endemic in Central and South America, is caused by the parasite Trypanosoma cruzi. Chagas disease is primarily transmitted by triatomine insects (also known as “kissing bugs”) that feed on blood. The parasites can also be transmitted through blood transfusions, organ transplants, or from mother to child during pregnancy.
For a complete picture of Trypanosomiasis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
